Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in

  News Archive

Shire to Combine with Baxalta
Tuesday, January 12, 2016
Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020.

First Insurance Coverage of NGS and Proteomic Diagnostic Platform
Tuesday, January 12, 2016
With this announcement next-generation sequencing and precision medicine has evolved from research to the clinical cancer setting.

OriGene Awarded Contract to Develop Monoclonal Antibodies for SISCAPA
Monday, January 11, 2016
OriGene Technologies have announced that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

Thermo Fisher Scientific to Acquire Affymetrix
Monday, January 11, 2016
Strengthens leadership in biosciences and genetic analysis.

Energy Sensor Identified As Potential Target for Cancer Drugs
Monday, January 11, 2016
An international research team formed by a University of Cincinnati (UC) cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells.

Antibacterial Properties of Clay Discovered
Monday, January 11, 2016
May be new answer to MRSA, other 'superbug' infections.

Pfizer, Adaptive Biotechnologies Collaborate
Monday, January 11, 2016
Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise.

Aelix Therapeutics Raises €11.5M for Therapeutic HIV Vaccine
Monday, January 11, 2016
Funds will support proof of concept studies for lead candidate HTI immunogen as a therapeutic vaccine against HIV infection.

Arquer Granted Permission to Launch Bladder Cancer Study
Monday, January 11, 2016
Arquer’s high sensitivity, ELISA test in study for Bladder Cancer consisting of a six month, multi-centre 800 patient clinical trial.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 4052

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos